DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications

Provider of Accessible Blood-Based Tests for Cancer Detection Highlights Results of Clinical Trial in Preeminent Peer-Reviewed Publication BALTIMORE and PALO ALTO, Calif., Oct. 21, 2024 /PRNewswire/ -- Today, DELFI Diagnostics, Inc., developer of accessible blood-based liquid biopsy tests...